Clinical trials: MAFLD
Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD)
Linzhi Jianghuang Fufang Huoxue Anshen Capsule for Non-alcoholic Fatty Liver
This is a randomized, double-blinded, placebo-controlled clinical trial aimed at evaluating the efficacy and safety of Linzhi Jianghuang Fufang Huoxue Anshen Capsule (LJF) for non-alcoholic fatty liver.
- Trial name
- LJF (NCT07637006)
- Testing
- Linzhi Jianghuang Fufang Huoxue Anshen Capsule (LJF)
- Volunteers
- 180 people
- Sponsor
- Hong Kong Baptist University
Metabolic Dysfunction-associated Fatty Liver Disease, Cirrhosis
Study on MAFLD-related Cirrhosis Prevention and Treatment Strategies
To establish a prospective, multicenter, biopsie-confirmed clinical cohort of MAFLD-related cirrhosis (F3-F4) in China, and analyze the clinical, histopathological features and natural outcomes of MAFLD-associated liver…
- Trial name
- SMART (NCT06135584)
- Testing
- Pioglitazone metformin tablets, Other drugs, Drug-free
- Volunteers
- 1,000 people
- Sponsor
- The Affiliated Hospital of Hangzhou Normal University
Non-alcoholic Fatty Liver Disease NAFLD
Hepatic Mitochondrial Metabolism in Fatty Liver Disease in Humans
The goal of this clinical trial is to investigate in healthy volunteers the mechanisms by which ethanol and lipids, the two key risk factors of steatotic liver disease (SLD), affect liver mitochondrial metabolism.
- Trial name
- ALPHA (NCT06559878)
- Testing
- 13C-α-Ketoisocaproic Acid Breath Test, Ethanol, Lipid Emulsion
- Where
- Finland
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Helsinki University Central Hospital
Metabolic Dysfunction-associated Fatty Liver Disease
The Potential Value and Impact of Diagnostic Biomarkers for MAFLD Using Machine Learning Methods
This is a case-control study that aims to build a predictive model for MAFLD based on machine learning.
- Trial name
- NCT06061640
- Where
- China
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- The First Affiliated Hospital of Zhejiang Chinese Medical University
Metabolic Dysfunction-Associated Steatotic Liver Disease
Ultrasound Liver Imaging for Classification of Metabolic Dysfunction-associated Steatotic Liver Disease
Tissue elasticity and viscosity correlate with pathology. These tissue properties are typically evaluated subjectively using palpation.
- Trial name
- NCT07373769
- Testing
- Ultrasound and magentic resonance imaging
- Where
- Canada
- Volunteers
- 145 people, healthy volunteers welcome
- Sponsor
- University of British Columbia
Metabolic Dysfunction-Associated Steatotic Liver Disease, Liver Fibrosis
Automated Passive Case-Finding for Advanced Liver Fibrosis in MASLD: The LiverSeek Programme
LiverSeek is a fully automated, passive case-finding programme for advanced liver fibrosis associated with metabolic dysfunction-associated steatotic liver disease (MASLD) in primary care.
- Conditions
- Metabolic Dysfunction-Associated Steatotic Liver Disease, Liver Fibrosis, Non-alcoholic Fatty Liver Disease NAFLD, Type 2 Diabetes Mellitus
- Trial name
- LiverSeek (NCT07658755)
- Where
- Spain
- Volunteers
- 3,000 people
- Sponsor
- Hospital General Universitario Gregorio Marañon
T2DM, MAFLD
The Effect of Alogliptin Combined With Actoplus Met on Glucose and Lipid Metabolism and Pancreatic Function in Patients With T2DM Complicated With MAFLD
To compare the efficacy and safety of the combination of alogliptin and actoplus met with that of actoplus met alone in improving the glucose and lipid metabolism and pancreatic function in T2DM patients complicated with MAFLD.
- Trial name
- NCT07289750
- Testing
- alogliptin and actoplus met, actoplus met
- Volunteers
- 80 people
- Sponsor
- The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Type 2 Diabetes
Risk of CKD in Diabetic Patients With MAFLD
This cross-sectional study of 300 participants investigates the risk of chronic kidney disease (CKD) in individuals with metabolic dysfunction-associated fatty liver disease (MAFLD) and type 2 diabetes.
- Trial name
- NCT06304844
- Testing
- transient elastography (Fibroscan)
- Volunteers
- 300 people
- Sponsor
- Sohag University
MAFLD
Clinical Study on the Treatment of MAFLD With Ganzhixiao Capsules
This trial is expected to enroll 138 MAFLD patients in one clinical center, who will be randomly divided into a placebo group and a Ganzhixiao capsule group in a 1:1 ratio.
- Trial name
- NCT06848907
- Testing
- ganzhixiao capsule
- Volunteers
- 138 people
- Sponsor
- Dong Hui
Hyperuricemia and MAFLD
Screening for Hyperuricemia in Patients With Metabolic Associated Fatty Liver Disease (MAFLD)
Due to the established correlation between serum uric acid (SUA) levels and metabolic associated fatty liver disease (MAFLD), this study aims to screen for hyperuricemia in all patients diagnosed with MAFLD.
- Trial name
- SUMA (NCT07053709)
- Volunteers
- 200 people
- Sponsor
- Assiut University
Metabolic Dysfunction-Associated Fatty Liver Disease, Obesity, Adolescent
Effect of L-citrulline and HIIT on Arterial Stiffness, Body Composition, and Lipid Profile in Adolescents with Steatosis Associated with Metabolic Dysfunction (MASLD)
Obesity and metabolic dysfunction-associated steatotic liver disease (MASLD) accelerate the appearance of arterial stiffness due to inflammatory and oxidative stress mechanisms producing increased vascular tone and increasing the…
- Conditions
- Metabolic Dysfunction-Associated Fatty Liver Disease, Obesity, Adolescent, Arterial Stiffness
- Trial name
- NCT05778266
- Testing
- L-citrulline, Carboxymethyl cellulose, High Intensity Intervals Training
- Where
- Mexico
- Volunteers
- 43 people
- Sponsor
- Universidad de Guanajuato
MAFLD, Metabolic Abnormalities
Frequency of MAFLD and Its Association With Nutritional Status and Metabolic Risk Factors in a Rural Population of Bangladesh
Metabolic dysfunction-associated fatty liver disease (MAFLD) is an increasingly recognized cause of chronic liver disease and is closely linked with obesity, metabolic abnormalities, and nutritional status.
- Conditions
- MAFLD, Metabolic Abnormalities, Obesity & Overweight
- Trial name
- NCT07470749
- Where
- Bangladesh
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Chronic Hepatitis B, Metabolic Associated Fatty Liver Disease
Analysis of Clinical Characteristics of Chronic Hepatitis B Combined With MAFLD in Different TCM Syndrome Types
This is a retrospective cross-sectional observational clinical study. We will collect clinical medical records of patients diagnosed with chronic hepatitis B combined with metabolic associated fatty liver disease who received…
- Trial name
- NCT07730736
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Foshan Hospital of Traditional Chinese Medicine
Fatty Liver Disease
Epidemiological Survey on Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)
To investigate the prevalence of Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) among adults in China
- Trial name
- MAFLD (NCT05421572)
- Testing
- Fibrotouch
- Where
- China
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Beijing Tsinghua Chang Gung Hospital
Non-alcoholic Fatty Liver Disease
Exercise and Cerebral Hemodynamics in MAFLD.
Arterial stiffness and endothelial dysfunction present in metabolic associated fatty liver disease (MAFLD) confer increased cardiovascular risk, which represents the leading cause of mortality in this group of patients.
- Trial name
- CERHEMAFLD (NCT05520697)
- Testing
- Nutritional intervention, Mental exercise., Physical training.
- Where
- Mexico
- Volunteers
- 42 people
- Sponsor
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Type 2 Diabetes (T2DM), Metabolic Dysfunction-Associated Steatotic Liver Disease
Cardiovascular Risk in T2DM With MAFLD: A Cohort Study
This study aims to address the following key scientific question by establishing a large-scale, high-standard clinical cohort: the independent contribution of MASLD and its progression to liver fibrosis on cardiovascular outcomes…
- Trial name
- NCT07706010
- Where
- China
- Volunteers
- 7,000 people
- Sponsor
- The Affiliated Hospital of Hangzhou Normal University
Metabolic Dysfunction-Associated Steatotic Liver Disease
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
The main purpose of the SYNERGY-OUTCOMES study is to find out whether retatrutide and tirzepatide can prevent major adverse liver outcomes (MALO) in people with high-risk metabolic dysfunction-associated steatotic liver disease…
- Trial name
- NCT07165028
- Testing
- Tirzepatide, Retatrutide
- Where
- 563 sites in United States, Argentina and 32 more
- Volunteers
- 4,500 people
- Sponsor
- Eli Lilly and Company
Pancreatic Exocrine Insufficiency
Screening for Pancreatic Exocrine Insufficieny in Metabolic Associated Fatty Liver Disease Patients
to investigate the frequency of PEI in MAFLD
- Trial name
- NCT05804409
- Testing
- FECAL ELASTASE
- Volunteers
- 70 people
- Sponsor
- Assiut University
MAFLD, Cholecystitis
Metabolic Dysfunction-Associated Fatty Liver Disease Impairs Intraoperative Indocyanine Green Fluorescence Cholangiography Quality: Development and Validation of a Predictive Model
Near-infrared fluorescence cholangiography has been shown to improve the clinical outcomes of laparoscopic cholecystectomy (LC).
- Conditions
- MAFLD, Cholecystitis, Gallbladder Polyps, Cholelithiasis
- Trial name
- NCT07297225
- Testing
- Retrospective observational study without intervention measures
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Zhujiang Hospital
Metabolic Dysfunction-Associated Steatotic Liver Disease
Using Digital Twin Technology and Clinical Decision Support Systems to Improve the Early Detection, Personalised Treatment, and Long-term Monitoring of Patients Across the Full Spectrum of Metabolic-associated Fatty Liver Disease (MAFLD).
The goal of this observational study is to create a detailed virtual model to better understand how Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) develops.
- Trial name
- ARTEMIS (NCT07430501)
- Testing
- Data recollection
- Where
- Spain
- Volunteers
- 7,720 people, healthy volunteers welcome
- Sponsor
- Hospital Universitari Vall d'Hebron Research Institute